Print

Algeta to Participate in Upcoming Investor Conference  
4/17/2013 10:56:31 AM

OSLO, NORWAY--(Marketwired - April 17, 2013) - Algeta ASA (OSE: ALGETA), a company focused on the development of novel targeted cancer therapeutics, announces that members of its senior management and IR teams will participate in the following investor conference:

Kempen & Co. 6(th) Healthcare/Life Sciences Conference

Date: 23 April 2013

Participants:

Thomas Ramdahl (Chief Technology Officer)

Renate Birkeli (IR)

Venue: Amsterdam, The Netherlands

About Algeta

Algeta is a company focused on developing novel targeted therapies for patients with cancer based on its alpha-pharmaceutical platform. The Company is headquartered in Oslo, Norway, and has a US subsidiary, Algeta US, LLC, based in Cambridge, MA performing commercial marketing operations in the US. Algeta is listed on the Oslo Stock Exchange (Ticker: ALGETA). For more information please visit www.algeta.com.

Algeta to Participate in Upcoming Investor Conference:

http://hugin.info/134655/R/1693399/556601.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Algeta ASA via Thomson Reuters ONE

[HUG#1693399]


For further information, please contact:

Mike Booth / Renate Birkeli
+47 23 00 67 32
Communications & Corporate Affairs
Email Contact

Media enquiries:

Mark Swallow
+44 207 638 9571
Citigate Dewe Rogerson
Email Contact

Knut Ekern
+47 22 04 82 00
Gambit Hill & Knowlton
Email Contact

Kari Watson
+1 781 235 3060
MacDougall Biomedical Communications
Email Contact

US investor enquiries:
Tricia Swanson
+1 646 378 2953

The Trout Group
Email Contact


//-->